https://www.rolvedon.com/study-design 2023-04-25 0.8 https://www.rolvedon.com/static/desktop-chart-01-d-11c8e3c0b14702f346cfe53f533c3f56.svg ROLVEDON® study design https://www.rolvedon.com/static/desktop-chart-01-m-0320612a279de93dfb1710fc25a72e84.svg ROLVEDON® study design https://www.rolvedon.com/static/shield-ffd02d9f37ebeeb5f74b338ea9ec5870.svg https://www.rolvedon.com/static/spectrum-c1091751c74ca5cd0a0f5a8a359942f8.svg Spectrum® logo https://www.rolvedon.com 2023-04-25 0.9 https://www.rolvedon.com/static/spectrum-c1091751c74ca5cd0a0f5a8a359942f8.svg spectrum pharmaceuticals logo. Click here to go to the website https://www.rolvedon.com/pdf/rolvedon-prescribing-information.pdf 2023-04-25 0.8 https://www.rolvedon.com/efficacy-safety 2023-04-25 0.8 https://www.rolvedon.com/static/mean-duration-chart-cb699ad7fa7d32b1aaee5ecd0172e706.svg Chart: Mean Duration of Severe Neutropenia https://www.rolvedon.com/static/mean-duration-chart-small-mobile-4-f8984af95c06e5a97e97802281c30bfb.svg Chart: Mean Duration of Severe Neutropenia https://www.rolvedon.com/static/study-1-91a6c024101b59c4488145de3da8c50c.svg Chart: Incidence and duration of Severe Neutropenia, Study 1 https://www.rolvedon.com/static/study-2-690730c7cf4bb9ebd331c8e8092c4019.svg Chart: Incidence and duration of Severe Neutropenia, Study 2 https://www.rolvedon.com/static/study-1-small-a42e060168bdc9e561f930fe7a2259b2.svg Chart: Incidence and duration of Severe Neutropenia, Study 1 https://www.rolvedon.com/static/study-2-small-f7941b6bfd21bc18d2e4be5050beef38.svg Chart: Incidence and duration of Severe Neutropenia, Study 2 https://www.rolvedon.com/static/4b8bf5f7d1c3b7ab4efd1227f14c436e/51d7c/person-1.png https://www.rolvedon.com/static/4b8bf5f7d1c3b7ab4efd1227f14c436e/d4144/person-1.png https://www.rolvedon.com/static/fcd17ad6eb3326f8acdeb1fcd25e1cf5/2906b/person-1-small.png https://www.rolvedon.com/static/fcd17ad6eb3326f8acdeb1fcd25e1cf5/d4144/person-1-small.png https://www.rolvedon.com/static/fcd17ad6eb3326f8acdeb1fcd25e1cf5/a5370/person-1-small.png https://www.rolvedon.com/static/mean-cycle-1-d-90d31fb2ea6718a84d67a642611cd6e4.svg Chart: Mean ANC Over Time in Cycle in Study 1 https://www.rolvedon.com/static/mean-cycle-1-m-4b19651c5ba2ee27ed0756b96ca39dd7.svg Chart: Mean ANC Over Time in Cycle in Study 1 https://www.rolvedon.com/static/mean-cycle-2-d-0bde8070d650e730951cb1d8883298f9.svg Chart: Mean ANC Over Time in Cycle in Study 2 https://www.rolvedon.com/static/mean-cycle-2-m-ab922d78e6787d45b3e22f1ae3f9968a.svg Chart: Mean ANC Over Time in Cycle in Study 2 https://www.rolvedon.com/static/12f5c757cc36d095e3135b2ea1a95bfc/30492/person-2.png a man with febrile neutropenia https://www.rolvedon.com/static/12f5c757cc36d095e3135b2ea1a95bfc/d4144/person-2.png a man with febrile neutropenia https://www.rolvedon.com/static/12f5c757cc36d095e3135b2ea1a95bfc/a5370/person-2.png a man with febrile neutropenia https://www.rolvedon.com/static/08e2c241d8b5d3c0f0b858e8a8032d84/1b97b/person-2-small.png a man with febrile neutropenia https://www.rolvedon.com/static/08e2c241d8b5d3c0f0b858e8a8032d84/d4144/person-2-small.png a man with febrile neutropenia https://www.rolvedon.com/static/08e2c241d8b5d3c0f0b858e8a8032d84/a5370/person-2-small.png a man with febrile neutropenia https://www.rolvedon.com/static/study-febrile-df222aaad556c759809b0ac1bcd4ce10.svg Chart: The incidence of febrile neutropenia https://www.rolvedon.com/static/study-febrile-small-79e7148a0702d03405d33b177f193161.svg Chart: The incidence of febrile neutropenia https://www.rolvedon.com/static/6620947426ef0ac9daf1e41935a3fd67/f0c16/person-3.png a woman who recently underwent chemotherapy https://www.rolvedon.com/static/6620947426ef0ac9daf1e41935a3fd67/d4144/person-3.png a woman who recently underwent chemotherapy https://www.rolvedon.com/static/6620947426ef0ac9daf1e41935a3fd67/a5370/person-3.png a woman who recently underwent chemotherapy https://www.rolvedon.com/static/0d47bbd346df30d17db58dd229b600ae/1b97b/person-3-small.png a woman who recently underwent chemotherapy https://www.rolvedon.com/static/0d47bbd346df30d17db58dd229b600ae/d4144/person-3-small.png a woman who recently underwent chemotherapy https://www.rolvedon.com/static/0d47bbd346df30d17db58dd229b600ae/a5370/person-3-small.png a woman who recently underwent chemotherapy https://www.rolvedon.com/static/mean-dsn-days-desktop-1-9f4ade8de518fe42e0cc9b7fbcbfe7d1.svg Chart: Mean DSN (Days) in Cycles 2 to 4 https://www.rolvedon.com/static/mean-dsn-days-small-mobile-8c64792ffad699e29f3ade48a4e59eef.svg Chart: Mean DSN (Days) in Cycles 2 to 4 https://www.rolvedon.com/static/408baab06e9ef0a4a9218a5b3f8922fe/73c85/person-4.png a woman who was recently diagnosed with early-stage breast cancer https://www.rolvedon.com/static/408baab06e9ef0a4a9218a5b3f8922fe/d4144/person-4.png a woman who was recently diagnosed with early-stage breast cancer https://www.rolvedon.com/static/408baab06e9ef0a4a9218a5b3f8922fe/a5370/person-4.png a woman who was recently diagnosed with early-stage breast cancer https://www.rolvedon.com/static/408baab06e9ef0a4a9218a5b3f8922fe/a7cbc/person-4.png a woman who was recently diagnosed with early-stage breast cancer https://www.rolvedon.com/static/794060d44eddff08bc4a3a566d01607e/81cd1/person-4-small.png a woman who was recently diagnosed with early-stage breast cancer https://www.rolvedon.com/static/794060d44eddff08bc4a3a566d01607e/d4144/person-4-small.png a woman who was recently diagnosed with early-stage breast cancer https://www.rolvedon.com/static/794060d44eddff08bc4a3a566d01607e/a5370/person-4-small.png a woman who was recently diagnosed with early-stage breast cancer https://www.rolvedon.com/static/spectrum-c1091751c74ca5cd0a0f5a8a359942f8.svg Spectrum® logo https://www.rolvedon.com/severe-neutropenia 2023-04-25 0.8 https://www.rolvedon.com/static/risk-eb78780587804a5ead0fc44b838be2f4.png Incremental risk of hospitalization visual https://www.rolvedon.com/static/severe-9784ce932ab406cac0e9f6e58f1b8170.svg Various brand art object https://www.rolvedon.com/static/spectrum-c1091751c74ca5cd0a0f5a8a359942f8.svg Spectrum® logo https://www.rolvedon.com/patient-support 2023-04-25 0.8 https://www.rolvedon.com/static/ROLVEDON-Distribution-Flashcard-df614f0dd58dcf417f7e0470b9834e9d.png https://www.rolvedon.com/static/computer-178fd3d1c1ab5dc0c43b2214eca89362.png https://www.rolvedon.com/static/spectrum-c1091751c74ca5cd0a0f5a8a359942f8.svg spectrum pharmaceuticals logo. Click here to go to the website /pdf/ROLVEDON_Returned_Goods_Policy.pdf 2023-04-25 0.8 https://www.rolvedon.com/administration 2023-04-25 0.8 https://www.rolvedon.com/static/Rolvedon_final_fullsize-10b-fea0ccffc791cb3487fef8e0e5a8f11e.png a hypodermic needle filled with a dose of rolvedon https://www.rolvedon.com/static/freeze-2028d59a2a411adcf8d8c0b5a7fcbeba.svg Freeze/cold https://www.rolvedon.com/static/spectrum-c1091751c74ca5cd0a0f5a8a359942f8.svg Spectrum® logo https://www.rolvedon.com/pdf/ROLVEDON_Distribution_Card.pdf 2023-04-25 0.7 https://www.rolvedon.com/moa 2023-04-25 0.8 https://www.rolvedon.com/static/moa-493130ac860c8030b1ade9f584bd52a8.png a molecular diagram that breaks down each component that makes up rolvedon. The three pieces include: Fc, flexible PEG linker, and G-CSF analog https://www.rolvedon.com/static/SpectrumMOAefla_peg_r2-d34bd2b4b99c2295aa03dc438b623453.png an illustration showing how rolvedon works within the body to combat severe neutropenia https://www.rolvedon.com/static/spectrum-c1091751c74ca5cd0a0f5a8a359942f8.svg spectrum pharmaceuticals logo. Click here to go to the website https://www.rolvedon.com/sitemap 2023-04-25 0.7 https://www.rolvedon.com/static/spectrum-c1091751c74ca5cd0a0f5a8a359942f8.svg spectrum pharmaceuticals logo. Click here to go to the website